Next Phase Newsletter

A philanthropic venture firm was established by a family trust to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. This US-based firm makes 4-5 investments each year of approximately $1-2 million into privately-held companies worldwide at both the seed and Series A stages. The firm operates under an evergreen structure and has made 49 investments to date.

While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), The firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. The firm looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round.

The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm headquartered in Asia manages over $1.2B AUM and makes initial investments generally around $5M, but has the capacity to invest much higher amounts depending on the opportunity and fit. While the firm’s focus is on more developed companies, the firm is actively seeking early-stage opportunities with strong global potential, and is open to considering those outside of their headquarters.

Within life sciences, the firm’s main focus is in therapeutics and digital therapeutics, but the firm is also interested in medical devices, diagnostics, and digital health/healthcare IT. The firm looks at all modalities and indications. When considering therapeutics companies, the firm prefers to invest in early clinical stage projects and tend to avoid investing in pre-clinical ones.

The firm has no specific company or management team requirements. The firm can act as either a lead or co-investor, and will seek board representation in companies they fund as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global, family-owned company with headquarters in Europe has offices all around the world. The firm’s venture fund focuses on early stage companies, and positions itself to be a strategic corporate partner to develop and support innovative technologies to commercialization in areas for growth opportunity. The firm’s venture fund typically makes $1-$5 million investments. The firm is seeking 4-5 investments in early-stage companies, start-ups including spinout companies from academia. The firm is geographically agnostic, and is open to investments from all over the world.

The firm is seeking outstanding ideas and promising technologies that are capable of generating a high level of customer interest. Besides early stage projects and seed investments, the firm aims to maximize the value of their entire portfolio, including the development of promising later stage investments and opportunities across all aforementioned the firm’s focus areas. The firm’s interest in Aesthetics comprises an anti-aging focus, including skin rejuvenation, body shaping and modification. The firm is open to all therapeutics, medical devices, and digital health / healthcare IT, as long as the technology serves an unmet need/gap in the aesthetics professionals’ daily practice.

The firm’s Neuroscience perspective includes, but is not limited to the treatment of movement disorders and adjacent indications, while the firm’s consumer healthcare business is open applicable b2b and d2c models for improving consumers’ wellbeing and sustainable quality of life.

The firm take pride in their long-standing commitment to both innovation and continuity. In line with their strategic interests, the firm is open to proactive and long-term engagement with their partners, and hope to provide much more than financial backing.

The firm seeks to directly connect investments to the firm’s global infrastructure by offering access to relevant experts in their scientific research network and providing commercial insights into global market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm actively funds, supports and advances life science technologies from early development through clinical proof-of-concept. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The firm has access to capital to support companies from seed investment through Series A and B financings and the size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the firm can invest directly as a Series A investment along with participation in related Series B investments. The firm is open to global opportunities.

The firm supports opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, the firm is open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly and supportive of first-time CEOs, the firm works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office invests in healthcare and technology companies. The firm partner with awesome entrepreneurs who are transforming healthcare – solving big problems and creating great companies. Typical investment is $200k-1M.

The firm’s interests include chronic eye diseases, diabetes, Parkinson’s, Alzheimer’s, cancer (breast & prostate), stroke, chronic kidney disease, AI, digital health, medical devices, telemedicine. The firm does not actively invest in therapeutics or diagnostics at this time.

The firm partners with resourceful entrepreneurs who have proven their ability to get results.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based invests strategically on behalf of a global pharmaceutical company. The firm will invest mostly in therapeutics, and a bit in digital health.

The firm is interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $15M over the life of an investment for therapeutics companies, and slightly less for digital health companies. The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments – the firm considers opportunities globally but focuses on Europe, Middle East and North America.

The firm is strategically mandated to invest in opportunities beyond the parent company’s core areas of business.  The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology (esp. new therapeutic modalities, such as cell / gene therapy), regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology and immunomodulation), tissue regeneration (stem cells, NCEs, biologics), anti-infectives with novel MOA, and microbiome; within digital health, the firm is interested in patient care management (i.e. diagnosis and monitoring of disease, prevention of onset and progression of disease including digital biomarkers, population management), medication adherence, digital companion therapy, and digital therapy as stand alone. The firm will also consider opportunities in other indication areas outside of the aforementioned key areas of interest. The firm generally invests in preclinical assets.

The firm invests in technologies of strategic importance the parent company. The firm only invests in privately held companies.  The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Western Europe current invests from their third fund which focuses on investments in Europe based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics ventures. The firm is agnostic regarding technologies and indication areas and invests in companies with assets 12 months or less to the clinic, as well as assets in phase 1 or 2.  (i.e Series A and Series B)

Moreover, the firm is a company builder, identifying academic projects with potential for company creation. The company has developed a specific model of collaboration between the academic, the firm and an industrial to create companies.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.